Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Genetically engineered BMSCs promote dopamine secretion and ameliorate motor dysfunction in a Parkinson's disease rat model

Wang C., Liu Y., Chang J., He Y., Yang P., Fu J.

Animal Study on Neuroinflammation, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40217082
PMCID
PMC11992172
DOI
10.1038/s41598-025-97557-4
Citations
2

Abstract (original English)

Regenerative therapy based on mesenchymal stem cells (MSCs) is regarded as a promising strategy for treating Parkinson's disease (PD). Previous studies have shown that mesenchymal stem cell transplantation has the potential to treat Parkinson's disease, but its specific mechanism of action is still unclear. In the present study, we generate genetically engineered bone marrow mesenchymal stem cells (BMSCs) encoding three critical genes (TH, DDC, and GCH1) for dopamine synthesis (DA-BMSCs). The DA-BMSCs maintain their MSCs characteristics and stable ability to secrete dopamine after passage. Moreover, the DA-BMSCs survived and functioned in a rat model of PD treated with 6-OHDA 8 weeks after transplantation. Histological studies showed that DA-BMSCs could differentiate into various functional neurons and astrocytes, and DA-BMSCs derived mature dopaminergic neurons extended dense neurites into the host striatum. Importantly, DA-BMSCs promoted the reconstruction of midbrain dopamine pathways by upregulating striatal dopamine and 5-HT levels and downregulating the levels of inflammatory factors including IL-6, TNF-α, and IL-10. These findings suggest that engineered mesenchymal stem cell transplantation for dopamine synthesis may be an attractive donor material for treating Parkinson's disease.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsRatsRats, Sprague-DawleyParkinson DiseaseDisease Models, AnimalDopamineOxidopamineMesenchymal Stem Cell TransplantationGenetic Engineering

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research